By Daniel Sabet · Cannabis CFO & Financial Advisor, GreenGrowth CPAs · 280E, Tax Strategy & Growth Planning · Los Angeles, CA | Published June 2026 | Cannabis Tax
July 6, 2026 is a tax deadline most cannabis operators have never heard of. IRS Revenue Procedure 2025-28, issued August 28, 2025 under the One Big Beautiful Bill Act, created a one-time window for eligible small businesses to file amended returns and retroactively elect immediate expensing of domestic research and experimental costs for tax years 2022, 2023, and 2024. Cannabis operators who conducted qualifying research activities in those years and capitalized those costs on their original returns may be able to recover them as a refund. The window is narrow. It closes July 6, 2026, or earlier if your statute of limitations under IRC Section 6511 has already run for a given year.
QUICK ANSWER
Cannabis operators with average annual gross receipts under $31 million for 2022 through 2024 who conducted qualifying domestic R&D activities in those years may be eligible for retroactive expensing relief under Rev. Proc. 2025-28. The deadline is July 6, 2026, or the earlier expiration of the statute of limitations under Section 6511 for each tax year. This is not the standard R&D credit on Form 6765. It is a separate expensing election under Section 174A created by the OBBBA.
R&D Tax Relief for Cannabis: At a Glance
- What it is: A retroactive election under Rev. Proc. 2025-28 to immediately expense domestic R&D costs under IRC Section 174A for tax years 2022 through 2024, filed via amended return or administrative adjustment request.
- Who it applies to: Small businesses with average annual gross receipts under $31 million for 2022, 2023, and 2024, measured under the Section 448(c) test and aggregated across all related entities.
- Key constraint: The July 6, 2026 deadline is a maximum. Your actual deadline for each year is the earlier of July 6 or the expiration of the Section 6511 statute of limitations for that year.
- Primary mistake: Assuming July 6 is the universal deadline without confirming when you filed your original 2022 return. A 2022 return filed April 15, 2023 without extension may have a statute window that already closed.
- Cannabis R&D that may qualify: Extraction method development, product formulation, cultivation process optimization, and proprietary compliance technology development.
- GreenGrowth's role: We confirm eligibility, check the statute of limitations for each open year, and prepare amended returns for qualifying cannabis operators before the deadline. Book a review before July 6 →
What Rev. Proc. 2025-28 Created and Why It Matters for Cannabis
Before the OBBBA, IRC Section 174 required businesses to capitalize domestic R&D costs and amortize them over five years, a rule that took effect in 2022 under the Tax Cuts and Jobs Act. Many small businesses did exactly that on their 2022, 2023, and 2024 returns. The OBBBA introduced Section 174A, which lets qualifying small businesses immediately expense those costs instead of spreading them over multiple years.
Rev. Proc. 2025-28 went further. It created a one-time exception that lets eligible businesses amend their already-filed returns for 2022, 2023, and 2024 to make the retroactive election. If you capitalized R&D costs in those years and the election produces a net benefit after the 280E analysis, an amended return could generate a refund. After July 6, 2026, that window closes permanently. No extension exists.
How This Differs from the Standard R&D Credit
This is a common source of confusion. The standard R&D credit under IRC Section 41, claimed on Form 6765, is a credit against tax liability. It reduces what you owe dollar for dollar. The Section 174A election under Rev. Proc. 2025-28 is about how you deduct the cost of R&D. It determines whether you spread that cost over five years or expense it all in year one. The two provisions interact through the Section 280C election, which governs how they work together when both apply. They are separate analyses with separate deadlines.
What Counts as Qualifying R&D for a Cannabis Operator
Under IRC Section 174, qualified research involves costs you incur to develop or improve a product or process in a way that eliminates technical uncertainty. The work must be experimental in nature. For cannabis operators, activities that can meet this standard include the following.
Extraction method development: Systematic testing and refinement of extraction techniques, solvent processes, or concentration methods. The key is documented iteration. Repeating a known process does not qualify. Developing or improving one does.
Cultivation process R&D: Research into lighting protocols, nutrient formulations, environmental controls, or yield optimization where the operator is testing and documenting outcomes to improve the process. Generic growing does not qualify. Structured process development does.
Product formulation: Development and testing of edible, concentrate, or topical formulations. Dosage research, stability testing, and formula iteration with documented outcomes can qualify.
Compliance technology development: If your operation built proprietary software for compliance tracking, inventory management, or METRC integration, the development costs may qualify. Off-the-shelf implementation does not. Original development work can.
▶ Does Your Cannabis Operation Have Qualifying R&D Activity?
Likely Qualifying
- Systematic extraction method development with documented testing
- Cultivation process improvement with tracked trial outcomes
- Product formulation and stability testing
- Proprietary compliance software development
- Process automation development tied to production
Generally Not Qualifying
- Routine quality control of existing products
- Adapting a known product for a specific customer
- Market research or consumer surveys
- Off-the-shelf software implementation
- Research funded under contract where you don't own the IP
💬 The Conversation Worth Having
A California extraction operator with $18 million in 2023 gross receipts came to us after seeing a mention of the July 6 deadline. They had been systematically developing and refining extraction ratios and cannabinoid formulations for three years. We reviewed their 2022 through 2024 R&D activity, confirmed qualifying expenditures under Section 174 standards, and prepared an amended return. The analysis took two weeks. The opportunity had been sitting there the whole time. The operators who miss this window will not know what they left behind.
The July 6 Deadline: What It Actually Means and the Statute Trap
July 6, 2026 is the outer deadline for amended returns under Rev. Proc. 2025-28. But for each individual tax year, your real deadline is the earlier of July 6 or the expiration of the statute of limitations under IRC Section 6511. That statute generally runs three years from the date you filed the original return.
The 2022 Trap You Need to Check Right Now
If your cannabis operation filed its 2022 federal return on the original deadline of April 15, 2023, without an extension, the three-year statute window for that year expired April 15, 2026. That is before July 6, 2026. Your 2022 year may already be closed. If you filed on extension and submitted your 2022 return in September or October 2023, the window extends to September or October 2026 and you are still inside it.
For 2023 and 2024, the statute windows are generally still open for most filers. Each year has its own window. Confirm the original filing date for each year before assuming eligibility. This is the first step we take in any R&D review. For more on how we handle amended returns and open statute analysis, see our amended return and tax planning services.
Not sure if your 2022 statute is still open? We can confirm in one conversation before July 6.
Book a Review →How 280E Interacts with the R&D Expensing Election
The 280E analysis is present in almost every cannabis tax question, and R&D expensing is no different. Section 280E blocks federal deductions for businesses that sell Schedule I controlled substances. Cannabis remains Schedule I. R&D costs expensed under Section 174A are deductions in the traditional sense, so 280E applies.
The path to deductibility runs through COGS. R&D costs tied to production activities, such as cultivation process development or extraction method research, can often be allocated to cost of goods sold. When that allocation holds, the expensing election produces real tax benefit. R&D costs tied to administrative, marketing, or sales functions face 280E disallowance and produce limited benefit. The same asset-function analysis used for bonus depreciation applies here. For our approach to cannabis tax compliance, including 280E interaction analysis, visit our cannabis services page.
KEY TAKEAWAYS
- ›Rev. Proc. 2025-28 created a one-time window for eligible small businesses to retroactively elect immediate expensing of domestic R&D costs for tax years 2022 through 2024. The window closes July 6, 2026.
- ›Eligibility requires average annual gross receipts under $31 million for 2022 through 2024, measured under the Section 448(c) test and aggregated across all related entities. MSOs must combine revenues across all license entities.
- ›July 6 is the maximum deadline, not a guaranteed one. Your actual deadline for each year is the earlier of July 6 or the Section 6511 statute of limitations expiration for that year.
- ›Cannabis operators who filed their 2022 return on April 15, 2023 without an extension may have a 2022 statute that expired April 15, 2026. Confirm your original filing dates before assuming eligibility for that year.
- ›Qualifying cannabis R&D includes extraction method development, cultivation process optimization, product formulation, and proprietary compliance technology development. Routine production does not qualify.
- ›280E applies to the R&D expensing deduction. R&D costs tied to production activities have the strongest path to deductibility. Costs tied to administrative or sales functions face 280E limits.
Frequently Asked Questions
IRS Revenue Procedure 2025-28, issued August 28, 2025, established a one-time window for eligible small businesses to file amended returns making retroactive Section 174A elections to immediately expense domestic R&D costs for tax years 2022, 2023, and 2024. The window closes July 6, 2026. After that date, the retroactive election is no longer available and standard rules apply going forward.
This deadline also covers Section 280C elections, which govern how the R&D expensing deduction interacts with the Section 41 R&D credit when both apply. July 6, 2026 is the outer limit. Your actual deadline for each year depends on when you filed the original return and whether the Section 6511 statute of limitations has already run.
To qualify, a cannabis operator must pass the small business gross receipts test under IRC Section 448(c). This requires average annual gross receipts under $31 million for 2022, 2023, and 2024, measured by aggregating gross receipts across all related entities under common control. An MSO with multiple license entities cannot test each entity separately. The entire group's revenues combine for the eligibility test.
Beyond the gross receipts test, the operator must have paid or incurred qualifying domestic R&D costs in one or more of the covered years. The activities must meet the technical definition of research and experimentation under IRC Section 174. Confirm both eligibility factors before preparing an amended return.
No. The retroactive election under Rev. Proc. 2025-28 relates to how R&D costs are deducted under IRC Section 174A. It determines whether you spread those costs over five years or expense them immediately. This is a deduction-side election, not a credit. The R&D credit under IRC Section 41, claimed on Form 6765, is a separate provision that reduces tax liability dollar for dollar.
Both provisions can apply to the same R&D activities. When they do, the Section 280C election governs how they interact. A cannabis CPA familiar with both provisions and the 280E framework needs to run both analyses together to determine the optimal election for your specific situation.
If the Section 6511 statute of limitations for the 2022 tax year has already expired, you cannot file an amended return for that year under Rev. Proc. 2025-28, even if you are otherwise eligible. The statute generally runs three years from the date you filed the original return. A 2022 return filed April 15, 2023 without an extension produced a statute window that expired April 15, 2026.
If your 2022 window has closed, the analysis shifts to 2023 and 2024, where the statute windows are generally still open for most filers. Each year is independent. You may still benefit from amended returns for 2023 and 2024 even if 2022 is no longer available. Confirm the original filing date for all three years before drawing conclusions.
Section 280E blocks federal deductions for cannabis businesses with cost of goods sold as the primary exception. R&D costs expensed under Section 174A are deductions subject to 280E. The benefit of the expensing election depends on whether the underlying R&D activity ties to a COGS-eligible production function or a 280E-restricted function.
Cultivation process development, extraction method research, and product formulation work tied directly to production have the strongest case for COGS allocation. That allocation allows the expensing deduction to reduce federal taxable income. R&D tied to administrative, sales, or marketing functions faces 280E disallowance. The net benefit requires a function-level analysis of each qualifying activity before filing an amended return.
We run a four-step process before recommending any amended return. First, we confirm the aggregated gross receipts test across all related entities for 2022 through 2024. Second, we verify the original filing dates to determine the open statute window for each year. Third, we review the original returns to identify R&D costs that were capitalized and amortized rather than immediately expensed. Fourth, we apply the 280E analysis to each qualifying activity to determine the net tax benefit after the interaction.
We only recommend filing an amended return when the analysis shows a clear net benefit after accounting for all costs. The work needs to happen now. July 6 is weeks away. To start an eligibility review, book a CFO Discovery Call with our team.
July 6 Is Weeks Away. The Review Has to Start Now.
GreenGrowth CPAs confirms eligibility, checks the statute of limitations window for each year, reviews original returns for capitalized R&D costs, and prepares amended returns for qualifying cannabis operators. We work with operators across California, New York, New Jersey, Minnesota, and Delaware.
KEY NUMBERS
July 6, 2026. After That, This Window Is Gone.
Cannabis operators with qualifying R&D activity in 2022 through 2024 have a closing window to recover previously capitalized costs. GreenGrowth CPAs can confirm your eligibility and statute window before the deadline passes.
Book Your Free CFO Discovery Call →GreenGrowth CPAs · Cannabis Tax Team
